DUBLIN and BRIDGEWATER, N.J., July 17, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Aaron Berg, President & CEO, and members of Amarin’s senior management team to discuss its second quarter 2024 results followed by Q&A on Wednesday, July 31st, 2024, at 8:00 a.m. ET. The conference call with management will follow the release of the Company’s second quarter 2024 financial results in the pre-market hours on July 31st.   To enhance engag ...

Core Viewpoint - Amarin Corporation's commercial partner EddingPharm has received regulatory approval from China's National Medical Products Administration (NMPA) for VASCEPA to reduce the risk of cardiovascular events in specific high-risk adult patients [1][2] Group 1: Regulatory Approval and Market Potential - VASCEPA is approved as an adjunct to statin therapy for adult patients with elevated triglyceride levels (≥150 mg/dL) and established cardiovascular disease or diabetes with additional risk factors [1][2] - EddingPharm is working to include VASCEPA in the National Reimbursement Drug Listing (NRDL), which covers 98% of the Chinese population, allowing for public reimbursement [2] Group 2: Cardiovascular Disease Context in China - Cardiovascular disease (CVD) accounts for 44-47% of all deaths in China, with an estimated 330 million patients suffering from CVD [3] - The World Heart Federation projects a 50% increase in cardiovascular events in China from 2010 to 2030 due to population aging and growth [3] Group 3: Financial Implications and Partnerships - Amarin will receive a regulatory milestone payment of $15 million from EddingPharm following the NMPA approval [4] - EddingPharm will pay Amarin tiered double-digit percentage royalties on net sales of VASCEPA in China [4] Group 4: Future Developments - NMPA has requested EddingPharm to conduct a post-approval study to verify VASCEPA's efficacy in reducing cardiovascular events in Chinese patients [3][4]

-- VASCEPA Approved by the National Medical Products Administration (NMPA) To Reduce the Risk of Cardiovascular Events as an Adjunct to Statin Therapy in Adult Patients with Elevated Triglyceride (TG) Levels (≥150 mg/dL) and Other High-Risk Characteristics as Studied in REDUCE-IT -- -- EddingPharm Now Working to Prepare for National Reimbursement and Drug Listing (NRDL) and Enhance the Commercial Launch of VASCEPA Across Mainland China -- DUBLIN and BRIDGEWATER, N.J., July 08, 2024 (GLOBE NEWSWIRE) -- Amari ...

Bangkok, Thailand, June 07, 2024 (GLOBE NEWSWIRE) -- LA BOUTIQUE This new location promises to be a premier destination for high-end fashion enthusiasts and tourists visiting Bangkok, Thailand. Celebrating 12 years in the fashion industry, LA BOUTIQUE has consistently pushed the boundaries of design and innovation, creating timeless pieces that captivate audiences worldwide. The brand’s exquisite collections have been worn by international celebrities such as Eva Longoria, Olivia Palermo, and Kristina Baza ...

-- Board Appoints Aaron Berg as President & CEO -- -- Patrick Holt to Step Down as President & CEO to Pursue Other Opportunities -- DUBLIN and BRIDGEWATER, N.J., June 04, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that the Company's Board of Directors has appointed Aaron Berg, currently Amarin's Executive Vice President and President of the U.S. Business, as President and Chief Executive Officer (CEO). The appointment of Mr. Berg follows the resignation of Patrick Holt as ...

-- Board Appoints Aaron Berg as President & CEO -- -- Patrick Holt to Step Down as President & CEO to Pursue Other Opportunities -- DUBLIN and BRIDGEWATER, N.J., June 04, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that the Company’s Board of Directors has appointed Aaron Berg, currently Amarin’s Executive Vice President and President of the U.S. Business, as President and Chief Executive Officer (CEO). The appointment of Mr. Berg follows the resignation of Patrick Holt as ...

-- Greek Ministry of Health approved VAZKEPA® (icosapent ethyl) for national reimbursement to reduce cardiovascular risk in statin-treated adult patients with elevated triglycerides (≥ 150 mg/ml [≥ 1.7 mmol/l) and other high-risk characteristics as studied in REDUCE-IT1 -- -- Approval marks seventh national reimbursement of VAZKEPA® in Europe -- -- Vianex S.A., one of the leading pharmaceutical companies in Greece, will commercialize VAZKEPA® as Amarin's exclusive distributor in the country -- DUBLIN, Irela ...

-- Greek Ministry of Health approved VAZKEPA® (icosapent ethyl) for national reimbursement to reduce cardiovascular risk in statin-treated adult patients with elevated triglycerides (≥ 150 mg/ml [≥ 1.7 mmol/l) and other high-risk characteristics as studied in REDUCE-IT1 -- -- Approval marks seventh national reimbursement of VAZKEPA® in Europe -- -- Vianex S.A., one of the leading pharmaceutical companies in Greece, will commercialize VAZKEPA® as Amarin’s exclusive distributor in the country -- DUBLIN, Irela ...

DUBLIN, Ireland and BRIDGEWATER, N.J., May 06, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that Patrick Holt, Amarin's president and chief executive officer, is scheduled to participate in fireside chat at the 2024 H.C. Wainwright 2nd Annual BioConnect Investor Conference. H.C. Wainwright 2nd Annual BioConnect Investor Conference (May 20th, 2024; NYC)Date/Time:May 20, 2024, 4:30 p.m. ETWebcast:https://journey.ct.events/view/a719062a-400f-406f-82d4-2463ef546624   The session ...

Amarin Corporation Plc (AMRN) reported first-quarter 2024 adjusted loss of 2 cents per share, which was narrower than the Zacks Consensus Estimate of a loss of 5 cents per share. The company had recorded an adjusted loss of 4 cents in the year-ago quarter.Total revenues were $56.5 million, which beat the Zacks Consensus Estimate of $51.0 million. However, revenues declined 34% from the year-ago quarter’s levels, owing to lower product revenues.Despite the better-than-expected results, shares of Amarin were ...